Here’s Why Lucid Diagnostics (LUCD) Declined in Q3

Core Insights - Minot Light Capital Partners reported a net return of 7.6% for Q3 2025, which underperformed against benchmarks, particularly the micro-cap benchmark's return of 17.1% [1] - The fund's top five holdings were highlighted, indicating the best investment picks for 2025 [1] Company Analysis: Lucid Diagnostics Inc. - Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage medical diagnostics technology company with a one-month return of 0.92% and a 52-week gain of 43.92% [2] - As of December 23, 2025, Lucid Diagnostics' stock closed at $1.10 per share, with a market capitalization of $144.209 million [2] - Lucid Diagnostics was noted as the second biggest detractor in the portfolio for the quarter, despite its FDA-approved DNA test, EsoGuard, which targets a multi-billion dollar market opportunity for early detection of esophageal precancer and cancer [3] - The company has strong clinical data and a unique market position, but adoption has been hindered by a lack of reimbursement [3]